Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the major shareholders of Eco-Boråstapeter in connection with sale to Litorina
Mandate

Vinge advises the major shareholders of Eco-Boråstapeter in connection with sale to Litorina

September 13, 2010

Vinge has advised the major shareholders of Eco-Boråstapeter in connection with the sale of their shares to Litorina. Eco-Boråstapeter is one of the leading wallpaper manufacturers in the Nordic countries. Litorina has acquired approximately two-thirds of the company’s shares and is thus the new majority shareholder. The new company’s shareholder base will also include members of the company’s board of directors and approximately 135 of Eco-Boråstapeter’s former employees. Eco-Boråstapeter had a turnover of approximately SEK 550 million in 2009 and has approximately 165 employees.

Vinge’s team consisted of responsible partner Björn Nicolai and associates Shoan Panahi, Viggo Becker-Ståhl and Gabriel Westin.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025